$23 billion US investment plan gains momentum as new center aims to accelerate AI-driven drug discovery and advanced therapies
San Diego, California, 12 February 2026...
DrugCLIP opens a new chapter in drug discovery with genome-scale virtual screening.
Beijing, China, 9 January 2026 – A new artificial intelligence system is changing...
AI-powered discovery platform EVA™ drives development of a highly selective T-cell engager showing over 90% tumor growth inhibition in pre-clinical studies.
London, 13 November 2025...
Neurocrine Biosciences, Inc. has officially published top-line data from a Phase 4 study named KINECT-PRO™ data, which showcases clinically meaningful and sustained effects of...
Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, has officially published results from...
